• Items
  • Login
  • Register

An Introduction to the Abbreviated NDA (ANDA), 505(b)(2) Applications, and Patent and Exclusivity Issues

Add to Cart
Back to Results
Recorded November 9, 2022 | On-Demand Webinar

Understand the generic drug approval pathway and requirements of sameness, bioequivalence, and therapeutic equivalence. Recognize patent listing and certification requirements and implications for Hatch-Waxman patent infringement cases and generic drug approval. Learn eligibility requirements and scope of various market exclusivities for innovator and generic products.

This session was recorded as part of FDLI’s virtual Introduction to Drug Law and Regulation course in November 2022.

Assign Members : 
Members Assigned | Assign all contacts Unassign all contacts

  • All
  • Assigned
  • Unassigned
Add New Contact

Add New Contact





Cancel
Save

Assign Full Name Account Name Email Role
Total Records - Showing Page

Discounts and special pricing for additional items will be applied once you add the item to your cart.
Previous Next